Very interesting report. I guess in case of younger patients and early use the results would be even much better.
IMHO one reason not to follow up with this is, that the manufacturer dont want to compete with his own more expensive monoclonals.
It´s sorry to say but If somebody has EDSS 6 or more, it may be difficult to imagine how something in this world can repair the brain destruction already done. However, it we mix in clinical trials patients with EDSS let say 2 and 5,5, old and young and put everything together it is expected that only marginal effect, if any can be seen in clinical trials.
Unfortunately looks like the situation is similar to cancer trials, where the most potent drugs will be used first for untreatable, metastatic cases and it takes 10 to 20 years before they will be moved to the position of first-line treatment.
Like in case of taxans for breast cancer. It is still not the standard first-line combination treatment, even if we know now well that in case of first-line treatment the 5 years relapse rate will be 2 times less.